OOS, OOT, OOC, and OOSC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OOS, OOT, OOC, and OOSC
Current GMPs demand full understandng of out-of-control concepts. This article contains bonus material.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 46-47

cGMP perspective

That said, the cGMPs still call for companies to have firm control of their processes, statistical or otherwise. Being out-of-statistical-control, but within specifications is not acceptable from a cGMP perspective because there is a higher probability of manufacturing defective product. Companies are required to show continuing due diligence, provide data and analysis to prove that the process is being brought into a state of statistical control, or provide a scientific and statistical study to explain why it cannot be controlled.

To summarize, for control charts, practical significance and OOT go together, and statistical significance and statistical control go together. There are four possible combinations, the control charts for which can be viewed together at http://PharmTech.com/ controlcharts:


Figure 1: Not out-of-trend and not out-of-statistical-control.
1. Not OOT and not OOSC: the ideal situation (see Figure 1)







Figure 2: Out-of-statistical-control but not out-of-trend. Fails Western Electric rule number 2 (7 points on the same side of the center line).
2. Not OOT but OOSC: cannot yet see a practical change, but failed one or more WE8 rules (see Figure 2)







Figure 3: Not out-of-statistical-control but is out-of-trend. Passes all 8 Western Electric rules.
3. OOT but not OOSC: can see a practical change that is not yet statistically significant (see Figure 3)







Figure 4: Out-of-trend and out-of-statistical-control.
4. OOT and OOSC: can see a practical change that is statistically significant (see Figure 4).






Finally, any of these four combinations can be OOS or not OOS as the specification concept is independent of trend (practical significance) and statistical significance.

Lynn D. Torbeck is a statistician at Torbeck and Assoc., 2000 Dempster Plaza, Evanston, IL 60202, tel. 847.424.1314,
, http://www.torbeck.org/.

References

1. FDA, Guidance for Industry: Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008)

2. FDA, Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, Oct. 2006)

3. L.D. Torbeck, Pharm. Technol. 34 (3), 21–23 (1999)

4. Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309, (2011)

5. L.D. Torbeck, Pharm. Technol. 34 (3), 76 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here